Advertisement

AAPS PharmSciTech

, 20:312 | Cite as

Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide

  • Yang Qu
  • Wen-Long Lai
  • Yuan-Rong Xin
  • Fei-Qin Zhu
  • Yuan Zhu
  • Li Wang
  • Yue-ping Ding
  • Ying XuEmail author
  • Hong-Fei LiuEmail author
Research Article

Abstract

To enhance efficiency, convenience, and safety of Parkinson’s disease (PD) treatment for geriatric patients, an advanced suspension of Levodopa/Benserazide hydrochloride (LD/BH) has been prepared by cation-exchange resin and used to synchronize sustained release of LD and BH by optimizing coating parameters and prescription. For the purpose, LD and BH were immobilized on the surface of cation-exchange resin, respectively. Based on HPLC results, the cation-exchange resin showed high loading capacity. The studies on drug loading mechanism indicated that both drugs were immobilized by electrostatic interaction rather than physical adsorption. After PEG modification, pretreated drug-resin complexes were coated by emulsion–solvent evaporation method. In order to control drug release in a sustained manner, coating parameters of drug-resin microcapsules were optimized respectively by single-factor analysis. Further, coating prescription of the microcapsules was optimized to synchronize sustained release of LD and BH in vitro by orthogonal design. Utilizing optimal LD-resin microcapsules and BH-resin microcapsules, LD/BH suspension, containing both of them, was prepared by an optimal formulation and characterized by accelerated test and pharmacokinetic study in vivo. The accelerated test confirmed high stability of LD/BH suspension. According to pharmacokinetic results in vivo, in contrast with LD/BH commercial tablets, LD/BH suspensions did not only synchronize sustained release of both drugs but also show good bioequivalence. As LD/BH sustained release suspension can synchronize sustained release of multiple active ingredients by oral administration, the suspension presents promising oral dosage forms for geriatric patients with PD.

An advanced Levodopa/Benserazide hydrochloride (LD/BH) suspension, prepared by cation-exchange resin and optimized microencapsulation, synchronizes sustained releases of LD and BH in vivo to benefit Parkinson’s disease treatment for geriatric patients.

KEY WORDS

levodopa benserazide hydrochloride sustained release suspension cation-exchange resin prescription optimization 

Notes

Funding Information

This manuscript has been sponsored by the National Natural Science Foundation of China [No. 51602656 and No. 21707053], Nature Science Foundation of Jiangsu Province [No. BK20140577 and No. BK20160546], Postdoctoral Science Foundation of Jiangsu Province [No. 2018K272C and No. 2018K057C], China Postdoctoral Science Foundation [No. 2017M610309 and 2019M651730], the Scientific Research Foundation of Jiangsu University [No. 16JDG054 and No.11JDG122], the Training Project of Jiangsu university for Young Key Teachers [No. 5521290003], Suzhou Gusu Technology Angels Project [No. CYTS2017016], the Zhenjiang key research and development plan [No. SH2017003], the Jurong City Blessed Land Excellence Program [No. 201607], and Jiangyin Industry Prospective Technology Research and Development Program [No. JY0602A010101180020PB].

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

12249_2019_1511_MOESM1_ESM.docx (25 kb)
ESM 1 (DOCX 24 kb)

References

  1. 1.
    Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci. 2018;10(109):1–19.Google Scholar
  2. 2.
    David M, Damian MH, James BR, Stephane L, Hartwig RS. The role of dopamine in the brain - lessons learned from Parkinson's disease. Neuroimage. 2019;190:79–93.CrossRefGoogle Scholar
  3. 3.
    Fatemeh NE, Andrei S. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Aging Neurosci. 2018;12(612):1–14.Google Scholar
  4. 4.
    Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(2 Supplement):253–61.CrossRefGoogle Scholar
  5. 5.
    Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytaryr®, an extended-release capsule formulation of carbidopa–levodopa. Clin Pharmacokinet. 2017;56(9):999–1014.CrossRefGoogle Scholar
  6. 6.
    Gasser UE, Fischer A, Timmermans JP, Arnet I. Pharmaceutical quality of seven generic levodopa/benserazide products compared with original Madopar®/Prolopa®. BMC Pharmacol Toxicol. 2013;14(1):24.CrossRefGoogle Scholar
  7. 7.
    Klietz M, Greten S, Wegner F, Höglinger GU. Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients. Drug Aging. 2019;36(6):511-30.CrossRefGoogle Scholar
  8. 8.
    Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2017;536:547–62.CrossRefGoogle Scholar
  9. 9.
    Yuan WE, Yang XX, Zheng RY, Cai YP, Liao ML, Liu ZG. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine. 2012;7:2077–86.CrossRefGoogle Scholar
  10. 10.
    Xie CL, Wang WW, Zhang SF, Yuan ML, Che JY, Gan J, et al. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep. 2014;4:7506–15.Google Scholar
  11. 11.
    Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson’s diseases. Nanomedicine. 2016;11(10):1267–85.CrossRefGoogle Scholar
  12. 12.
    Guo XD, Chang RK, Hussain MA. Ion-exchange resins as drug delivery carriers. J Pharm Sci. 2009;98(11):3886–902.CrossRefGoogle Scholar
  13. 13.
    Bhise K, Shaikh S, Bora D. Taste mask, design and evaluation of an oral formulation using ion exchange resin as drug carrier. AAPS PharmSciTech. 2008;9(2):557–62.CrossRefGoogle Scholar
  14. 14.
    Jeong SH, Park K. Drug loading and release properties of ion-exchange resin complexes as a drug delivery matrix. Int J Pharm. 2008;361(1–2):26–32.CrossRefGoogle Scholar
  15. 15.
    Anand V, Kandarapu R, Garg S. Ion-exchange resins: carrying drug delivery forward. Drug Discov Today. 2001;6(17):905–14.CrossRefGoogle Scholar
  16. 16.
    Akkaramongkolporn P, Ngawhirunpat T, Nunthanid J, Praneet O. Effect of a pharmaceutical cationic exchange resin on the properties of controlled release diphenhydramine hydrochloride matrices using Methocel K4M or Ethocel 7cP as matrix formers. AAPS PharmSciTech. 2008;9(3):899–908.CrossRefGoogle Scholar
  17. 17.
    Sun CS, Liu HF, Zhao X, He H, Pan WS. In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. Drug Dev Ind Pharm. 2013;39(1):62–6.CrossRefGoogle Scholar
  18. 18.
    Liu HF, Chen C, Liu D, Pan WS, He Y, Zhang DD, et al. Preparation, evaluation and formulation optimization of sustained release microcapsuled ion-exchange resin beads containing ambroxol hydrochloride. Lat Am J Pharm. 2015;34(10):2054–60.Google Scholar
  19. 19.
    Liu HF, Shi SS, Sun CS, Zhao X, Shen S, He H. Investigation of the pharmacokinetics of a novel sustained release metformin hydrochloride suspension with ion exchange resin as carriers in beagle dogs. Afr J Pharm Pharmaco. 2012;6(7):502–4.Google Scholar
  20. 20.
    Liu HF, Liu D, Chen C, He Y, Zhu FQ, Zhang P, et al. Preparation and evaluation of carbinoxamine maleate sustained release suspensions with ion exchange resin as the carriers. Lat Am J Pharm. 2017;36(4):797–809.Google Scholar
  21. 21.
    Cao J, Liu HF, Pan WS, Sun CS, Feng YS, Zhong H, et al. The preparation of the sustained release metformin hydrochloride microcapsules by the Wurster fluidized bed. Pak J Pharm Sci. 2014;27(4):779–84.PubMedGoogle Scholar
  22. 22.
    Taek HS, Sung HI, Min SG, Eun SL, Myoung H, Chang HK, et al. Novel extended-release multiple-unit system of imidafenacin prepared by fluid-bed coating technique. AAPS PharmSciTech. 2018;9(6):2639–45.Google Scholar
  23. 23.
    Crawford RR, Esmerian OK. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J Pharm Sci. 2010;60(2):312–4.CrossRefGoogle Scholar
  24. 24.
    Fujimori J, Yoshihashi Y, Yonemochi E, Terada K. Application of Eudragit RS to thermo-sensitive drug delivery systems: I. Effect of temperature on drug permeability through membrane consisting of Eudragit RS/PEG 400 blend polymers. J Control Release. 2002;50(3):408–12.Google Scholar
  25. 25.
    Fujimori J, Yoshihashi Y, Yonemochi E, Terada K. Application of Eudragit RS to thermo-sensitive drug delivery systems: II. Effect of temperature on drug permeability through membrane consisting of Eudragit RS/PEG 400 blend polymers. J Control Release. 2005;102(1):49–57.CrossRefGoogle Scholar
  26. 26.
    Guidance for industry extended-release solid oral dosage forms: development, evaluation and application of in vitro-in vivo correlations. USP. 1997.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Yang Qu
    • 1
    • 2
  • Wen-Long Lai
    • 1
  • Yuan-Rong Xin
    • 1
  • Fei-Qin Zhu
    • 3
  • Yuan Zhu
    • 1
  • Li Wang
    • 1
  • Yue-ping Ding
    • 4
  • Ying Xu
    • 1
    Email author
  • Hong-Fei Liu
    • 1
    • 5
    Email author
  1. 1.College of PharmacyJiangsu UniversityZhenjiangChina
  2. 2.Chia Tai Qingjiang Pharmaceutical Industry Co., LtdHuaianChina
  3. 3.Chia Tai Tianqing Pharmaceutical Group Co., LtdNanjingChina
  4. 4.Jiangsu Sihuan biopharmaceutical Co., LtdWuxiChina
  5. 5.Zhangjiagang Xinchuang Biological Technology Co., LtdZhenjiangChina

Personalised recommendations